Tiragolumab
- Generic Name
- Tiragolumab
- Drug Type
- Biotech
- CAS Number
- 1918185-84-8
- Unique Ingredient Identifier
- 6XG22YQM2Z
- Background
Tiragolumab is under investigation in clinical trial NCT04513925 (A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)).
Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
- Conditions
- Relapsed Refractory Multiple MyelomaMultiple Myeloma
- Interventions
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Multiple Myeloma Research Consortium
- Target Recruit Count
- 14
- Registration Number
- NCT04150965
- Locations
- 🇺🇸
Hackensack Meridian Medical Center, Hackensack, New Jersey, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Emory University, Atlanta, Georgia, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Conditions
- Multiple MyelomaNon-Hodgkin LymphomaB-Cell Lymphoma
- Interventions
- First Posted Date
- 2019-08-05
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT04045028
- Locations
- 🇺🇸
Virginia Cancer Specialists (Fairfax) - USOR, Fairfax, Virginia, United States
🇺🇸Clinical Research Alliance, Westbury, New York, United States
🇺🇸University of Pennsylvania; School of Medicine, Philadelphia, Pennsylvania, United States
Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor
- Conditions
- Non-Small Cell Lung CancerSolid Tumor
- Interventions
- First Posted Date
- 2019-06-06
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 46
- Registration Number
- NCT03977467
- Locations
- 🇺🇸
Florida Cancer Specialists - East, West Palm Beach, Florida, United States
🇺🇸Florida Cancer Specialists - Panhandle, Tallahassee, Florida, United States
🇺🇸Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
- Conditions
- Urothelial CarcinomaBladder Cancer
- Interventions
- First Posted Date
- 2019-03-11
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 272
- Registration Number
- NCT03869190
- Locations
- 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇫🇷Institut Claudius Regaud, Toulouse, France
🇺🇸UCLA Department of Medicine, Los Angeles, California, United States
Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma
- Conditions
- Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage II Esophageal Adenocarcinoma AJCC v8Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage III Esophageal Adenocarcinoma AJCC v8
- Interventions
- Procedure: Conventional Surgery
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT03784326
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Preoperative Immunotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck
- Conditions
- CarcinomaHead and Neck CancerCancerSquamous Cell Carcinoma
- Interventions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Alain Algazi
- Target Recruit Count
- 55
- Registration Number
- NCT03708224
- Locations
- 🇺🇸
University of San Francisco, California, San Francisco, California, United States
A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT03563716
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of
🇺🇸Arizona Oncology Associates, PC - HAL, Tempe, Arizona, United States
🇺🇸SCRI Florida Cancer Specialists South, Fort Myers, Florida, United States
Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma
- Conditions
- Pathologic Stage IIIB Cutaneous Melanoma AJCC v8Pathologic Stage IIIA Cutaneous Melanoma AJCC v8Clinical Stage III Cutaneous Melanoma AJCC v8Pathologic Stage IIIC Cutaneous Melanoma AJCC v8Pathologic Stage III Cutaneous Melanoma AJCC v8Pathologic Stage IIID Cutaneous Melanoma AJCC v8
- Interventions
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 59
- Registration Number
- NCT03554083
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Other: Radiation
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 314
- Registration Number
- NCT03337698
- Locations
- 🇺🇸
Christiana Care Health Services, Newark, Delaware, United States
🇺🇸Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley, Las Vegas, Nevada, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
- Conditions
- Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
- Interventions
- First Posted Date
- 2017-09-13
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 410
- Registration Number
- NCT03281369
- Locations
- 🇦🇺
Blacktown Hospital, Blacktown, New South Wales, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇮🇱Rambam Health Care Campus, Haifa, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.